<PAGE>
Total Number of Pages: 3
--
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: May 23, 2000
Commission File Number: 0-26208
================================================================================
KERAVISION, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 77-0328942
(State of Incorporation) (I.R.S. Employer
Identification No.)
48630 MILMONT DRIVE
FREMONT, CA 94538
(Address of principal executive offices)
(510) 353-3000
(Registrant's telephone number)
<PAGE>
ITEM 5. OTHER EVENTS
On May 15, 2000, KeraVision, Inc. announced that Razorfish, Inc., the global
digital solutions provider, is developing a new consumer web site for
KeraVision, Inc. Further details regarding this announcement are contained in
the Company's news release dated May 15, 2000, attached as an exhibit hereto
and incorporated by reference herein.
On May 18, 2000, KeraVision, Inc. announced, Intacs micro-inserts, a
flexible new vision correction product for people with mild nearsightedness, is
being introduced to consumers in more than 20 cities this week in the first
major advertising and direct mail campaign since the product was approved.
Further details regarding this announcement are contained in the Company's news
release dated May 18, 2000, attached as an exhibit hereto and incorporated by
reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.41 KeraVision, Inc. News Release dated May 15, 2000
99.42 KeraVision, Inc. News Release dated May 18, 2000
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KERAVISION, INC.
/s/Mark Fischer-Colbrie
-----------------------
Mark Fischer-Colbrie
Vice President, Finance and
Administration and Chief Financial
Officer(Principal Financial and
Accounting Officer)
Date: May 23, 2000
3
<PAGE>
Exhibit 99.41
Razorfish Teams Up with KeraVision to Reach Vision Correction Consumers. New
web site is scheduled to launch in June.
FREMONT, CA -- May 15, 2000 -- Razorfish, Inc. (NASDAQ: RAZF), the global
digital solutions provider, today announced it is developing a new
consumer web site for KeraVision, Inc. (NASDAQ: KERA), developer of
Intacs micro-inserts for correcting mild nearsightedness (myopia).
The site, which is set to officially launch next month, will help educate
consumers about a new category of vision correction, Intacs micro-
inserts, as an alternative to eyeglasses, contact lenses and procedures
that permanently alter the eye's central optical zone. The new site will
also direct interested consumers to the most experienced eye doctor in
their area.
Chosen as one of "The Year's Top 10 Medical Advances" by CNN and Health
magazine, Intacs are a new, FDA-approved, non-laser option for correcting
mild nearsightedness, a condition that affects an estimated 20 million
adult Americans.
KeraVision President and Chief Operating Officer John Galantic said, "We
see this Internet initiative as a central part of a strategy to build
brand awareness for Intacs and drive procedure volume for the experienced
Intacs surgeons who make up our `Fast Track' provider network."
Galantic continued, "KeraVision believes this strategy is consistent with
our consumer research indicating that most Intacs wearers are highly
educated, cautious in their buying decisions, and likely to use the
Internet to research their options before choosing a vision correction
procedure."
He said the company will launch a consumer marketing program - to include
advertising and direct mail - that is intended to direct consumers to the
new web site where they will be linked to experienced Intacs surgeons in
their area.
Don Goodman, client partner at Razorfish, said, "Razorfish's goal is to
establish a strong digital brand for Intacs through a combination of
strategy, design and technology. By making complex vision care choices
easier, we believe KeraVision and Razorfish can create a user experience
that will be of true value to consumers."
Special features of KeraVision's new site will include:
- -- video testimonials by Intacs wearers
- -- flash-based graphics and intuitive architecture
- -- on-line vision test that will help people self-qualify for Intacs
- -- interactive question and answer section
- -- pre-qualification for consumer financing
- -- referral to a local high-volume Intacs provider
The site will also offer a secured area where Intacs-trained physicians
and referring optometrists can read new clinical study data and medical
bulletins, learn more about Intacs surgical techniques, find out about
upcoming events such as Intacs training programs, and download tools that
will help build their practice.
KeraVision later plans to add a secured area for marketing staffs of Fast
Track practices so that they can read about new product information,
special events, and ways to improve client service.
The company said it plans to release additional details about the new
Intacs consumer marketing program soon.
About Razorfish
Founded in 1995, Razorfish leverages digital technologies to help
companies invent and reinvent the way they do business. The company
delivers a complete set of end-to-end solutions including strategy,
design, and technology services across platforms, devices, and networks.
With offices in Amsterdam, Boston, Hamburg, Helsinki, Los Angeles,
London, New York, San Francisco, Stockholm and Oslo, Razorfish employs
more than 1,600 people and is headquartered in New York.
Recent Razorfish clients include Nissan, Excite, Vodafone Airtouch,
Nokia, and Charles Schwab. Additional information about Razorfish may be
found at ww.razorfish.com.For further information, visit
http://www.razorfish.com.
About KeraVision
KeraVision, founded in 1986, is the developer of Intacs micro-inserts for
correcting mild myopia, which was named one of "The Year's Top 10 Medical
Advances" by CNN and Health magazine. Approved by the FDA in 1999, Intacs
are a flexible and convenient option to eyeglasses, contact lenses and
vision correction surgeries that permanently alter the eye's central
optical zone. The company's patented Intacs technology is also being
developed for the possible treatment of hyperopia (farsightedness);
myopia (nearsightedness) in wider ranges than presently approved by the
FDA; astigmatism; and keratoconus, a corneal thinning disease.
Forward-Looking Statement Disclaimer for Razorfish
Certain statements made in this press release, are not statements of
historical fact and may constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Readers are cautioned that a number of risks and factors could cause
actual events to differ materially from those indicated in the "forward-
looking statements." Such risk factors include, without limitation,
Razorfish's ability to successfully integrate acquisitions, manage our
growth and international operations effectively, compete in a highly
competitive market, retain our professionals and other risk factors
identified from time-to-time in our filings with the Securities and
Exchange Commission.
Forward-Looking Statement Disclaimer for KeraVision
Except for the historical information, the matters discussed in this news
release are forward-looking statements. Actual results may differ
materially due to a variety of factors, including market acceptance of
Intacs micro-prescription inserts and the need for additional capital to
fund future business operations, as well as other risk factors described
under the heading "Risk Factors" contained in KeraVision's Form 10-K for
the year ended Dec. 31, 1999, as well as in other SEC filings.
####
Contacts:
For Razorfish:
James Pearson
Razorfish, Inc.
(212) 798-6701
[email protected]
Cindy Riveglia
Lois Paul & Partners for Razorfish, Inc.
(781) 238-5786
[email protected]
For KeraVision:
Mick Taylor
KeraVision, Inc.
(510) 353-3075
[email protected]
Andrew Lavin
Lavin Communications
(212) 290-9540
[email protected]
<PAGE>
Exhibit 99.41
FOR IMMEDIATE RELEASE
Intacs Ad Campaign Is Rolled Out in Over 20 Markets
"Power and Freedom" themes invite mildly nearsighted consumers to
switch from eyeglasses and contacts to new non-LASIK product
FREMONT, CA (May 18, 2000) - Intacs micro-inserts, a flexible new vision
correction product for people with mild nearsightedness (myopia), is
being introduced to consumers in more than 20 cities this week in the
first major advertising and direct mail campaign since the product was
approved by the Food and Drug Administration.
Developed by KeraVision, Inc. (Nasdaq: KERA), Intacs are the first FDA-
approved non-laser option for surgically correcting mild nearsightedness
- - a segment largely unpenetrated by laser correction manufacturers
despite the segment's potential size of about 22 million adult consumers.
Intacs were recently named one of "The Year's Top 10 Medical Advances" by
CNN and Health magazine.
Radio, print and direct mail are targeted to support a core group of
"Fast Track" practices that are leading the consumer launch of Intacs.
The company plans to spend up to $5 million as this consumer campaign is
expanded to support additional "Fast Track" practices.
KeraVision President and Chief Operating Officer John Galantic said, "The
new Intacs campaign is targeted at contact lens and eyeglass wearers who
are interested in permanent vision correction but apprehensive about
being locked into a permanent choice for the rest of their lives. Intacs
offer consumers crisp, clear, maintenance-free vision, with the
flexibility to allow changes in prescription as people's eyesight changes
naturally with age. These are the unique benefits behind the new
campaign theme, `The Power to Change Your Vision, the Freedom to Change
Your Mind.'"
Developed from in-depth qualitative and quantitative consumer research
conducted last year, the campaign is designed to direct consumers to
"Fast Track" practices in over 20 cities in order to build on these
practices' already growing Intacs procedure volume. The company expects
the program to provide a marketing model that will work in other cities
to support additional Intacs surgeons.
Galantic continued, "Based on our research, the mild myope is more risk
averse than higher myopes who account for most of today's vision
correction surgery consumers. We believe KeraVision has a unique
opportunity to connect with mild myopes who are tired of contacts and
eyeglasses but nervous about surgical procedures that permanently alter
their cornea. In our opinion, Intacs answer people's concerns about
permanent surgery as well as their desire for a safe, effective, flexible
alternative to lenses."
The STAR Group will manage co-branding strategy
The STAR Group in Cherry Hill, NJ, was named agency of record for the
account. The agency will manage the Intacs "co-branding" strategy that is
designed to, first, build awareness for Intacs and, second, direct
interested consumers to experienced "Fast Track" practices in each
market.
Cities included in this first phase of KeraVision's consumer co-branding
campaign range in size from Chicago and San Francisco to Fayetteville, AR
and Moreno Valley, CA.
In addition, a new Intacs web site, under development by Razorfish, is
scheduled for June launch. Advertising and direct mail will be used to
help direct consumers to the site where they can learn more about Intacs
and be linked to a Fast Track practice in their area.
KeraVision, founded in 1986, is the developer of Intacs micro-inserts for
correcting mild myopia, which was named one of "The Year's Top 10 Medical
Advances" by CNN and Health magazine. Approved by the FDA in 1999, Intacs
are a flexible and convenient option to eyeglasses, contact lenses and
vision correction surgeries that permanently alter the eye's central
optical zone. The company's patented Intacs technology is also being
developed for the possible treatment of hyperopia (farsightedness);
myopia (nearsightedness) in wider ranges than presently approved by the
FDA; astigmatism; and keratoconus, a corneal thinning disease.
Forward-Looking Statement Disclaimer
Except for the historical information, the matters discussed in this news
release are forward-looking statements. Actual results may differ
materially due to a variety of factors, including market acceptance of
Intacs prescription inserts, the need for additional capital to fund
future business operations, the inability to successfully market and sell
products, competitive products and technologies, and other risk factors
described under the heading "Risk Factors" contained in KeraVision's Form
10-K for the year ended Dec. 31, 1999, as well as in other SEC filings.
####
Contacts:
For investors:
Mark Fischer-Colbrie
(510) 353-3000
[email protected]
For news media:
Mick Taylor
KeraVision, Inc.
(510) 353-3075
[email protected]
Andrew Lavin
Lavin Communications
(212) 290-9540
